Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,622 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02316028 | Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)(DECIT) | completed | Phase 1 / Phase 2 | 11 | Universitair Ziekenhuis BrusselOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT00972881 | Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer(EXCITE) | completed | Phase 1 / Phase 2 | 82 | University College, LondonOTHER |
| 1 |
| Oct 25, 2017 |
| clinicaltrials |
| NCT02129257 | Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer(AMALTHEA) | completed | Phase 2 | 73 | Hellenic Cooperative Oncology GroupOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT02278133 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | completed | Phase 1 / Phase 2 | 20 | Array BioPharmaINDUSTRY | 10 | Oct 9, 2017 | clinicaltrials |
| NCT00682786 | Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma | completed | Phase 2 | 135 | Washington University School of MedicineOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00309179 | A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors | completed | Phase 2 | 41 | Eisai Inc.INDUSTRY | 2 | Sep 14, 2017 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT00847119 | Xeloda and Bevacizumab to Treat Rectal Cancer(xeberecto) | completed | Phase 2 | 43 | Institut Català d'OncologiaOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01623206 | Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding | completed | Phase 2 | 30 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01333709 | Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma(GRECCAR4) | completed | Phase 2 | 150 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT00865189 | A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer(INOVA) | completed | Phase 2 | 91 | Hoffmann-La RocheINDUSTRY | 1 | Aug 4, 2017 | clinicaltrials |
| NCT01040000 | QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer | completed | Phase 1 / Phase 2 | 94 | Precision Biologics, IncINDUSTRY | 1 | Aug 4, 2017 | clinicaltrials |
| NCT00875771 | Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients(AVAXIRI) | completed | Phase 2 | 80 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00885885 | Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases(PLANET) | completed | Phase 2 | 80 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01704703 | Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques(ULTRA) | completed | Phase 2 | 72 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00326495 | BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2017 | clinicaltrials |
| NCT01013805 | Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer(PROArCT) | completed | Phase 2 | 41 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02223078 | Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.(CC4) | completed | Phase 2 | — | Cancer Advances Inc.INDUSTRY | 1 | Jun 20, 2017 | clinicaltrials |
| NCT00582660 | Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib(UAB0040) | completed | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2017 | clinicaltrials |
| NCT01383707 | A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer | completed | Phase 2 | 77 | Hoffmann-La RocheINDUSTRY | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00381862 | Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00636610 | A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | completed | Phase 2 | 199 | Genentech, Inc.INDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT00468910 | Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer | completed | Phase 2 | 79 | National Cancer Institute (NCI)NIH | 1 | May 31, 2017 | clinicaltrials |
| NCT01418222 | FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 194 | Genentech, Inc.INDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT00842257 | Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer | completed | Phase 2 | 20 | Massachusetts General HospitalOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT03146377 | Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 32 | The University of Hong KongOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01051167 | Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer(CEBIFOX) | completed | Phase 2 | 59 | Martin Schuler, Prof. Dr. med.OTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT00004005 | Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin | completed | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT00828984 | Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00030563 | Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver | completed | Phase 2 | — | University of WashingtonOTHER | 2 | Apr 17, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT00002842 | Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer | completed | Phase 2 | 49 | City of Hope Medical CenterOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01292356 | Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response | completed | Phase 2 | 28 | Poitiers University HospitalOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01047293 | RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 47 | University of UtahOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01523431 | Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients | completed | Phase 2 / Phase 3 | 583 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00153816 | Vitamin D/Calcium Polyp Prevention Study | completed | Phase 2 / Phase 3 | 2,813 | Dartmouth-Hitchcock Medical CenterOTHER | 2 | Mar 15, 2017 | clinicaltrials |
| NCT01150877 | High Dose Vitamin D Study | completed | Phase 1 / Phase 2 | 40 | University of British ColumbiaOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02526134 | Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum(FIDUCOR) | completed | Phase 2 | 29 | Institut Paoli-CalmettesOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01802684 | OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer(VELVET) | completed | Phase 2 | 49 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00303875 | Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight | completed | Phase 2 | 641 | Duke UniversityOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00335504 | Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia | completed | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01749956 | 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer | completed | Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00203411 | Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer | completed | Phase 2 | 45 | Translational Oncology Research InternationalOTHER | 1 | Feb 6, 2017 | clinicaltrials |
| NCT00056030 | Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer | completed | Phase 2 | 73 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 24, 2017 | clinicaltrials |
| NCT01507103 | Tecemotide (L-BLP25) in Rectal Cancer(SPRINT) | completed | Phase 2 | 124 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jan 13, 2017 | clinicaltrials |
| NCT02694718 | A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer | completed | Phase 2 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02236884 | The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer | completed | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00016952 | Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 2 | 19 | Alliance for Clinical Trials in OncologyOTHER | 2 | Dec 7, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Oct 27, 2017source: clinicaltrials